BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson's Disease

(identifier: NCT05819359)
For more information about BIAL, please visit: www.bial.com

References:

 den?Heijer?JM?et?al. Br J?Clin?Pharmacol. 2021 Sep; 87(9):3561-3573;  Guedes L. et al. Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase). Presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS), Copenhagen, Denmark. August 27–31, 2023 APDA, www.apdaparkinson.org/what-is-parkinsons, accessed October 30 2024 Smith L, Schapira AHV.?Cells.?2022 Apr 8;11(8):1261 Gan-Or, Ziv et al. "Differential effects of severe vs mild GBA mutations on Parkinson disease." Neurology vol. 84,9 (2015): 880-7. doi:10.1212/WNL.0000000000001315

Logo - https://mma.prnewswire.com/media/2585238/BIAL_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/bial-announces-first-patient-out-in-its-phase-2-clinical-trial-of-bia-28-6156---a-novel-therapy-for-gba1-parkinsons-disease-302343261.html